title: Postoperative nausea and vomiting after myringoplasty under continuous sedation using midazolam with or without remifentanil.
abstract: OBJECTIVE
  This prospective study evaluated the effects of continuous sedation using midazolam, with or without remifentanil, on postoperative nausea and vomiting (PONV) in patients undergoing myringoplasty.
  
  
  METHODS
  Sixty patients undergoing myringoplasty were sedated with midazolam in the presence of remifentanil (group MR), or after saline injection instead of remifentanil (group M).
  
  
  RESULTS
  Three patients (10%) in group M complained of nausea; two vomited. Four patients (13%) in group MR complained of nausea and vomited within 24 h after surgery. Rescue drugs were given to the six patients who vomited. No significant difference was detected between the two groups regarding the incidence or severity of nausea, incidence of vomiting, or need for rescue drugs.
  
  
  CONCLUSIONS
  Midazolam-based continuous sedation can reduce PONV after myringoplasty. Compared with midazolam alone, midazolam with remifentanil produced no difference in the incidence or severity of nausea, incidence of vomiting, or need for rescue drugs.
authors.affiliation: Department of Anesthesiology and Pain Medicine, School of Medicine, Hallym University, Chuncheon 200-704, Korea.
authors.forename: Ji Su
authors.initials: JS
authors.lastname: Jang
authors.forename: Jun Ho
authors.initials: JH
authors.lastname: Lee
authors.forename: Jae Jun
authors.initials: JJ
authors.lastname: Lee
authors.forename: Won Jae
authors.initials: WJ
authors.lastname: Park
authors.forename: Sung Mi
authors.initials: SM
authors.lastname: Hwang
authors.forename: Soo Kyung
authors.initials: SK
authors.lastname: Lee
authors.forename: So Young
authors.initials: SY
authors.lastname: Lim
mesh_terms: D000328:Adult; D000367:Age Factors; D005260:Female; D006801:Humans; D008297:Male; D008874:Midazolam / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D009225:Myringoplasty / Q000009:adverse effects*; D010880:Piperidines / Q000009:adverse effects* / Q000627:therapeutic use; D020250:Postoperative Nausea and Vomiting / Q000139:chemically induced*; D011446:Prospective Studies; D000077208:Remifentanil; D012737:Sex Factors; D014839:Vomiting / Q000139:chemically induced*
chemical_list: D010880:Piperidines; D000077208:Remifentanil; D008874:Midazolam